• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    10 Health Care Stocks With Whale Alerts In Today's Session

    11/17/23 12:35:27 PM ET
    $ABBV
    $DXCM
    $GEHC
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ABBV alert in real time by email

    This whale alert can help traders discover the next big trading opportunities.

    Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

    Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels.

    Below are some instances of options activity happening in the Health Care sector:

    Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
    ABBV PUT TRADE NEUTRAL 11/17/23 $140.00 $293.7K 9.4K 1.4K
    MOR CALL SWEEP BEARISH 01/19/24 $10.00 $48.1K 15.3K 737
    DXCM PUT TRADE BULLISH 01/19/24 $102.50 $300.0K 248 600
    LLY CALL SWEEP BULLISH 11/24/23 $600.00 $34.8K 834 565
    MRTX PUT TRADE BEARISH 03/15/24 $45.00 $30.0K 662 500
    WAT CALL SWEEP BULLISH 11/17/23 $250.00 $118.1K 874 363
    GEHC CALL TRADE BEARISH 04/19/24 $50.00 $33.2K 395 354
    UNH CALL TRADE BULLISH 12/15/23 $540.00 $34.0K 2.9K 321
    IMGN CALL SWEEP NEUTRAL 01/16/26 $17.00 $52.1K 150 150
    NTLA CALL TRADE BEARISH 09/20/24 $40.00 $35.0K 590 120

    Explanation

    These itemized elaborations have been created using the accompanying table.

    • For ABBV (NYSE:ABBV), we notice a put option trade that happens to be neutral, is expiring today. Parties traded 1329 contract(s) at a $140.00 strike. The total cost received by the writing party (or parties) was $293.7K, with a price of $221.0 per contract. There were 9491 open contracts at this strike prior to today, and today 1402 contract(s) were bought and sold.

    • Regarding MOR (NASDAQ:MOR), we observe a call option sweep with bearish sentiment. It expires in 63 day(s) on January 19, 2024. Parties traded 292 contract(s) at a $10.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $48.1K, with a price of $165.0 per contract. There were 15342 open contracts at this strike prior to today, and today 737 contract(s) were bought and sold.

    • Regarding DXCM (NASDAQ:DXCM), we observe a put option trade with bullish sentiment. It expires in 63 day(s) on January 19, 2024. Parties traded 600 contract(s) at a $102.50 strike. The total cost received by the writing party (or parties) was $300.0K, with a price of $500.0 per contract. There were 248 open contracts at this strike prior to today, and today 600 contract(s) were bought and sold.

    • Regarding LLY (NYSE:LLY), we observe a call option sweep with bullish sentiment. It expires in 7 day(s) on November 24, 2023. Parties traded 50 contract(s) at a $600.00 strike. This particular call needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $34.8K, with a price of $699.0 per contract. There were 834 open contracts at this strike prior to today, and today 565 contract(s) were bought and sold.

    • For MRTX (NASDAQ:MRTX), we notice a put option trade that happens to be bearish, expiring in 119 day(s) on March 15, 2024. This event was a transfer of 500 contract(s) at a $45.00 strike. The total cost received by the writing party (or parties) was $30.0K, with a price of $60.0 per contract. There were 662 open contracts at this strike prior to today, and today 500 contract(s) were bought and sold.

    • For WAT (NYSE:WAT), we notice a call option sweep that happens to be bullish, is expiring today. Parties traded 93 contract(s) at a $250.00 strike. This particular call needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $118.1K, with a price of $1270.0 per contract. There were 874 open contracts at this strike prior to today, and today 363 contract(s) were bought and sold.

    • Regarding GEHC (NASDAQ:GEHC), we observe a call option trade with bearish sentiment. It expires in 154 day(s) on April 19, 2024. Parties traded 14 contract(s) at a $50.00 strike. The total cost received by the writing party (or parties) was $33.2K, with a price of $2376.0 per contract. There were 395 open contracts at this strike prior to today, and today 354 contract(s) were bought and sold.

    • Regarding UNH (NYSE:UNH), we observe a call option trade with bullish sentiment. It expires in 28 day(s) on December 15, 2023. Parties traded 40 contract(s) at a $540.00 strike. The total cost received by the writing party (or parties) was $34.0K, with a price of $850.0 per contract. There were 2925 open contracts at this strike prior to today, and today 321 contract(s) were bought and sold.

    • Regarding IMGN (NASDAQ:IMGN), we observe a call option sweep with neutral sentiment. It expires in 791 day(s) on January 16, 2026. Parties traded 100 contract(s) at a $17.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $52.1K, with a price of $490.0 per contract. There were 150 open contracts at this strike prior to today, and today 150 contract(s) were bought and sold.

    • Regarding NTLA (NASDAQ:NTLA), we observe a call option trade with bearish sentiment. It expires in 308 day(s) on September 20, 2024. Parties traded 100 contract(s) at a $40.00 strike. The total cost received by the writing party (or parties) was $35.0K, with a price of $350.0 per contract. There were 590 open contracts at this strike prior to today, and today 120 contract(s) were bought and sold.

    Options Alert Terminology
    - Call Contracts: The right to buy shares as indicated in the contract.
    - Put Contracts: The right to sell shares as indicated in the contract.
    - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it.
    - Premium/Option Price: The price of the contract.

    For more information, visit our Guide to Understanding Options Alerts or read more news on unusual options activity.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABBV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABBV
    $DXCM
    $GEHC
    $IMGN

    CompanyDatePrice TargetRatingAnalyst
    Intellia Therapeutics Inc.
    $NTLA
    3/2/2026Mkt Perform → Outperform
    William Blair
    Eli Lilly and Company
    $LLY
    2/25/2026$1250.00Outperform
    RBC Capital Mkts
    AbbVie Inc.
    $ABBV
    2/25/2026$260.00Outperform
    RBC Capital Mkts
    Eli Lilly and Company
    $LLY
    2/20/2026$1350.00Overweight
    Barclays
    AbbVie Inc.
    $ABBV
    2/20/2026$275.00Overweight
    Barclays
    Waters Corporation
    $WAT
    2/10/2026$360.00In-line
    Evercore ISI
    Waters Corporation
    $WAT
    2/10/2026$425.00Buy
    Citigroup
    Waters Corporation
    $WAT
    2/10/2026$400.00Overweight
    Barclays
    More analyst ratings

    $ABBV
    $DXCM
    $GEHC
    $IMGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fearon Richard H bought $306,340 worth of shares (1,000 units at $306.34), increasing direct ownership by 43% to 3,302 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    3/10/26 4:21:34 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EVP, Chief Financal Officer Sylvain Jereme M was granted 48,774 shares and covered exercise/tax liability with 18,950 shares, increasing direct ownership by 24% to 153,292 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    3/10/26 4:01:57 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Executive Chair Sayer Kevin R was granted 32,749 shares and covered exercise/tax liability with 32,498 shares, increasing direct ownership by 0.06% to 409,241 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    3/10/26 4:02:03 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $ABBV
    $DXCM
    $GEHC
    $IMGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Intellia Therapeutics upgraded by William Blair

    William Blair upgraded Intellia Therapeutics from Mkt Perform to Outperform

    3/2/26 12:43:05 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    RBC Capital Mkts initiated coverage on Eli Lilly with a new price target

    RBC Capital Mkts initiated coverage of Eli Lilly with a rating of Outperform and set a new price target of $1,250.00

    2/25/26 7:51:49 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on AbbVie with a new price target

    RBC Capital Mkts initiated coverage of AbbVie with a rating of Outperform and set a new price target of $260.00

    2/25/26 7:48:26 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $DXCM
    $GEHC
    $IMGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026

    New registry study data shows that long-term use of Dexcom G7 supports weight management and lowers A1C for people with Type 2 diabetes who aren't on insulin therapy1, reinforcing the need to broaden CGM access beyond insulin-treated populations. During its symposium on Thursday, March 12, Dexcom will share upcoming product features across its global portfolio. Two in-booth, expert-led presentations on Thursday, March 12, and Friday, March 13 will showcase the first consensus‑based CGM competency framework to give healthcare professionals a clear, role‑aligned structure for delivering confident, consistent CGM support.2   DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose

    3/11/26 2:00:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    GE HealthCare announces U.S. FDA 510(k) clearance for View, a next‑generation diagnostic viewer enabling anywhere‑access to radiologists

    Built for the demands of modern imaging, View streamlines workflows, and helps enhance patient care as the advanced diagnostic viewer powering the Genesis Radiology Workspace GE HealthCare today announced that View, the powerful viewer within the Genesis™ Radiology Workspace, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). Designed as a fast, diagnostic, zero‑footprint viewer, View serves as the core anchor of the Genesis Radiology Workspace.2 This next‑generation solution aims to transform radiology workflows, unify the user experience, and empower radiologists with greater efficiency and precision. Studies show that radiologists spend up to 44% of the

    3/9/26 9:00:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

    ABBV-295 treatment showed clinically meaningful body weight reduction from -7.75% to -9.79% (least-squares mean) at week 12 (weekly dosing), to -7.86% to -9.73% at week 13 (every other week and monthly dosing after week 5)1ABBV-295 demonstrated a favorable tolerability profile at all evaluated dose levels.  No serious adverse events were reported1Data support continued development of ABBV-295 as a potentially differentiated treatment for chronic weight management, with a non-incretin-based mechanism of action NORTH CHICAGO, Ill., March 9, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced positive topline results1 from the multiple ascending dose (MAD) part of its Phase 1 study evaluati

    3/9/26 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $DXCM
    $GEHC
    $IMGN
    SEC Filings

    View All

    UnitedHealth Group Incorporated filed SEC Form 8-K: Regulation FD Disclosure

    8-K - UNITEDHEALTH GROUP INC (0000731766) (Filer)

    3/9/26 4:33:13 PM ET
    $UNH
    Medical Specialities
    Health Care

    SEC Form PRE 14A filed by AbbVie Inc.

    PRE 14A - AbbVie Inc. (0001551152) (Filer)

    3/9/26 4:31:02 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by Eli Lilly and Company

    PRE 14A - ELI LILLY & Co (0000059478) (Filer)

    3/6/26 4:35:56 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $DXCM
    $GEHC
    $IMGN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    10/18/24 4:38:13 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form

    10/17/24 1:29:31 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SKYRIZI issued to ABBVIE INC

    Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-7) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/18/2024. Application Category: BLA, Application Number: 761262, Application Classification:

    6/21/24 4:38:17 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $DXCM
    $GEHC
    $IMGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fearon Richard H bought $306,340 worth of shares (1,000 units at $306.34), increasing direct ownership by 43% to 3,302 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    3/10/26 4:21:34 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Cohen Fred E bought $1,402,500 worth of shares (150,000 units at $9.35), increasing direct ownership by 261% to 207,453 units (SEC Form 4)

    4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)

    1/7/26 4:05:06 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    President & COO Leach Jacob Steven bought $1,001,702 worth of shares (18,200 units at $55.04), increasing direct ownership by 6% to 331,697 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    11/10/25 7:13:08 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $ABBV
    $DXCM
    $GEHC
    $IMGN
    Leadership Updates

    Live Leadership Updates

    View All

    Dexcom Appoints Rick Osterloh to Board of Directors

    DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Rick Osterloh to its Board of Directors, effective February 26, 2026. Mr. Osterloh is a highly accomplished technology executive with more than 20 years of leadership experience across consumer hardware, platform strategy and large-scale product operations. He currently serves as Senior Vice President, Platforms & Devices at Google, where he leads a unified group spanning the company's portfolio of advanced consumer technologies. This includes Android, Google Play, Chrome, and Google's Devices and Services Portfolio—Pixel phones, Google Nest smart home devices, and Fitbit wearables. Und

    2/26/26 4:15:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Waters Completes Combination with BD's Biosciences & Diagnostic Solutions Businesses

    Announces appointment of Claire M. Fraser, Ph.D., to its Board of DirectorsForms a global life sciences and diagnostics leader focused on high-volume testing in regulated applicationsAnnounces formation of four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials SciencesMILFORD, Mass., Feb. 9, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) ("Waters") today announced it has completed the previously announced combination with the Biosciences & Diagnostic Solutions businesses of Becton, Dickinson and Company (NYSE:BDX) ("BD"). The transaction forms a global life sciences and diagnostics leader, equipped with best-in-class technologies

    2/9/26 8:40:00 AM ET
    $BDX
    $WAT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $DXCM
    $GEHC
    $IMGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by GE HealthCare Technologies Inc.

    SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    11/12/24 12:53:28 PM ET
    $GEHC
    Medical Electronics
    Health Care

    Amendment: SEC Form SC 13G/A filed by Waters Corporation

    SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

    11/12/24 11:54:03 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Eli Lilly and Company

    SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

    10/23/24 5:17:34 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $DXCM
    $GEHC
    $IMGN
    Financials

    Live finance-specific insights

    View All

    Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

    HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half of 2027Process underway to reactivate global sites for MAGNITUDE-2 Phase 3 clinical trial of nex-z in ATTRv-PN; enrollment completion expected in second half of 2026FDA engagement ongoing to resolve clinical hold on MAGNITUDE Phase 3 clinical trial of nex-z in ATTR-CM Ended 2025 with approximately $605 million in cash, cash equivalents and marketable securities; expected to fund operations into the second half of 2027 CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical com

    2/26/26 7:30:00 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    UnitedHealth Group Board Authorizes Payment of Quarterly Dividend

    The UnitedHealth Group (NYSE:UNH) board of directors has authorized payment of a cash dividend of $2.21 per share, to be paid on March 17, 2026, to all shareholders of record of UNH common stock as of the close of business March 9, 2026. About UnitedHealth Group UnitedHealth Group (NYSE:UNH) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health

    2/25/26 6:50:00 AM ET
    $UNH
    Medical Specialities
    Health Care

    AbbVie Declares Quarterly Dividend

    NORTH CHICAGO, Ill., Feb. 19, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE:ABBV) today declared a quarterly cash dividend of $1.73 per share.  The cash dividend is payable May 15, 2026, to stockholders of record at the close of business on April 15, 2026.Since the company's inception in 2013, AbbVie has increased its dividend by more than 330 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of

    2/19/26 9:37:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care